Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Heavy alcohol consumption is a major cause of morbidity and mortality. Globally, alcohol per-
capita consumption rose from 5.5 litres in 2005 to 6.4 litres in 2016 and is projected to …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

Liver cancer epidemiology is changing due to increasing alcohol consumption, rising
prevalence of obesity, and advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) …

Nonalcoholic fatty liver (NAFL) and its sequelae are growing health problems. We performed
a genome-wide association study of NAFL, cirrhosis and hepatocellular carcinoma, and …

Nonalcoholic fatty liver disease (NAFLD) is the leading chronic liver disease worldwide. Its
more advanced subtype, nonalcoholic steatohepatitis (NASH), connotes progressive liver …

One quarter of the global population is estimated to have nonalcoholic fatty liver disease
(NAFLD). The incidence of nonalcoholic steatohepatitis (NASH) is projected to increase by …

Non-alcoholic fatty liver disease (NAFLD) is projected to become the leading cause of
hepatocellular carcinoma (HCC) in many countries. Many risk factors for NAFLD are also …

Conclusions Our findings indicate that LINC00665 is involved in the NF‐κB signaling
activation in HCC cells and that the inflammatory LINC00665/PKR/NF‐κB loop plays …

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …